Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

The preservative is in a small share of flu shots and has been studied for decades. Experts say it’s safe — despite Kennedy’s long opposition.

The Trump administration’s new vaccine advisers endorsed this fall's flu vaccines late last week, but only those that don't ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.